<DOC>
	<DOCNO>NCT01019694</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety patient acceptability COMBIVENT RESPIMAT Inhalation Spray compare COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler ( CFC-MDI ) free combination ATROVENT Hydrofluoroalkane ( HFA ) albuterol Hydrofluoroalkane ( HFA ) inhalation aerosol .</brief_summary>
	<brief_title>Combivent Respimat 1-year Safety Study Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign informed consent consistent International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) guideline prior participation trial . 2 . Male female patient 40 year age old . 3 . Patients must current exsmokers smoke history 10 packyears . ( Patients never smoke cigarette must exclude ) Pack Years = Number cigarettes/day x year smoke 20 cigarettes/pack 4 . All patient must diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) ( P954381 ) , must meet follow spirometric criterion Visit 1 : Relatively stable , moderate severe airway obstruction postbronchodilator Forced Expiratory Volume one second ( FEV1 ) &lt; 80 % predict normal FEV1/Forced Vital Capacity ( FVC ) &lt; 70 % . Spirometry do baseline approximately 1/2 hour follow 4 inhalation albuterol . Predicted normal value calculate accord European Coal Steel Community ( ECSC ) , European Community Coal Steel ( ECCS ) , ( R941408 ) . For Height measure inch Males : FEV1 predict ( L ) = 4.30 x [ height ( inch ) / 39.37 ] 0.029 x age ( yr ) 2.49 Females : FEV1 predict ( L ) = 3.95 x [ height ( inch ) / 39.37 ] 0.025 x age ( yr ) 2.60 For Height measure meter Males : FEV1 predict ( L ) = 4.30 x [ height ( meter ) ] 0.029 x age ( year ) 2.49 Females : FEV1 predict ( L ) = 3.95 x [ height ( meter ) ] 0.025 x age ( year ) 2.60 5 . Patients must able perform study related procedure maintain study record study period require protocol . 6 . Patients must able inhale medication competent manner RESPIMAT inhaler meter dose inhaler ( MDI ) . Exclusion criterion : 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients recent history ( i.e. , one year less ) myocardial infarction . 3 . Patients hospitalize treated heart failure within past year . 4 . Patients clinically unstable lifethreatening cardiac arrhythmia require intervention change drug therapy within past year . 5 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient fully cure squamous cell treat basal cell carcinoma allow ) . 6 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis . 7 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 . 8 . Patients current diagnosis asthma . 9 . Patients history significant alcohol drug abuse . 10 . Patients know active tuberculosis . 11 . Patients use beta blocker medication exclude . Cardioselective beta blocker allow caution . Beta blocker eye medication treatment nonnarrow angle glaucoma allow . 12 . Patients regularly use daytime oxygen therapy 1 hour per day Continuous Positive Airway Pressure ( CPAP sleep apnea allow ) . 13 . Patients use oral corticosteroid medication dose excess equivalent 10 mg prednisone per day 20 mg every day , except require treatment exacerbation study . 14 . Pregnant nursing woman . 15 . Women childbearing potential use medically approve mean contraception ( i.e. , oral injectable contraceptive , intrauterine device diaphragm spermicide , transdermal hormonal patch ) . Abstinence accept medically approve mean contraception . Female patient consider childbearing potential unless surgically sterilize hysterectomy bilateral tubal ligation , postmenopausal least two year . 16 . Patients know hypersensitivity anticholinergic drug , component ipratropium bromide/albuterol RESPIMAT solution include Benzalkonium chloride ( BAC ) Ethylenediaminetetraacetic acid ( EDTA ) ipratropium bromide/albuterol Chlorofluorocarbons ( CFC ) MDI Hydrofluoroalkane ( HFA ) component . 17 . Previous participation study . ( The patient reenroll study . ) 18 . Patients currently participate another interventional study . 19 . Patients take investigational drug within 1 month 6 half life ( whichever great ) prior screen . 20 . Patients currently pulmonary rehabilitation program schedule participate program study period .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>